Literature DB >> 28081485

The elucidation of non-classical MHC class II antigen processing through the study of viral antigens.

Asha Purnima Veerappan Ganesan1, Laurence C Eisenlohr2.   

Abstract

By convention, CD4+ T cells are activated predominantly by Major Histocompatibility Complex class II-bound peptides derived from extracellular (exogenous) antigens. It has been known for decades that alternative sources of antigen, particularly those synthesized within the antigen-presenting cell, can also supply peptides but the impact on TCD4+ responses, sometimes considerable, has only recently become appreciated. This review focuses on the contributions that studies of viral antigen have made to this shift in perspective, concluding with discussions of relevance to rational vaccine design, autoimmunity and cancer immunotherapy.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28081485      PMCID: PMC5346044          DOI: 10.1016/j.coviro.2016.11.009

Source DB:  PubMed          Journal:  Curr Opin Virol        ISSN: 1879-6257            Impact factor:   7.090


  72 in total

1.  Compromised influenza virus-specific CD8(+)-T-cell memory in CD4(+)-T-cell-deficient mice.

Authors:  Gabrielle T Belz; Dominik Wodarz; Gabriela Diaz; Martin A Nowak; Peter C Doherty
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

2.  Antigen-specific CD4 T-cell help rescues exhausted CD8 T cells during chronic viral infection.

Authors:  Rachael D Aubert; Alice O Kamphorst; Surojit Sarkar; Vaiva Vezys; Sang-Jun Ha; Daniel L Barber; Lilin Ye; Arlene H Sharpe; Gordon J Freeman; Rafi Ahmed
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-12       Impact factor: 11.205

3.  Enzymatic reduction of disulfide bonds in lysosomes: characterization of a gamma-interferon-inducible lysosomal thiol reductase (GILT).

Authors:  B Arunachalam; U T Phan; H J Geuze; P Cresswell
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-18       Impact factor: 11.205

4.  In vivo requirement for Atg5 in antigen presentation by dendritic cells.

Authors:  Heung Kyu Lee; Lisa M Mattei; Benjamin E Steinberg; Philipp Alberts; Yun Hee Lee; Alexander Chervonsky; Noboru Mizushima; Sergio Grinstein; Akiko Iwasaki
Journal:  Immunity       Date:  2010-02-18       Impact factor: 31.745

5.  Cutting edge: MHC class II-restricted killing in vivo during viral infection.

Authors:  Evan R Jellison; Sung-Kwon Kim; Raymond M Welsh
Journal:  J Immunol       Date:  2005-01-15       Impact factor: 5.422

6.  Sequence analysis of peptides bound to MHC class II molecules.

Authors:  A Rudensky; P Preston-Hurlburt; S C Hong; A Barlow; C A Janeway
Journal:  Nature       Date:  1991-10-17       Impact factor: 49.962

7.  MHC class II-restricted presentation of intracellular antigen.

Authors:  S Weiss; B Bogen
Journal:  Cell       Date:  1991-02-22       Impact factor: 41.582

8.  Nuclear location of an endogenously expressed antigen, EBNA1, restricts access to macroautophagy and the range of CD4 epitope display.

Authors:  Carol S Leung; Tracey A Haigh; Laura K Mackay; Alan B Rickinson; Graham S Taylor
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-19       Impact factor: 11.205

9.  Isolation and characterization of rat liver amphisomes. Evidence for fusion of autophagosomes with both early and late endosomes.

Authors:  T O Berg; M Fengsrud; P E Strømhaug; T Berg; P O Seglen
Journal:  J Biol Chem       Date:  1998-08-21       Impact factor: 5.157

10.  Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles.

Authors:  R M Chicz; R G Urban; J C Gorga; D A Vignali; W S Lane; J L Strominger
Journal:  J Exp Med       Date:  1993-07-01       Impact factor: 14.307

View more
  8 in total

1.  Protein Vaccination Directs the CD4+ T Cell Response toward Shared Protective Epitopes That Can Be Recalled after Influenza Virus Infection.

Authors:  Ajitanuj Rattan; Katherine A Richards; Zackery A G Knowlden; Andrea J Sant
Journal:  J Virol       Date:  2019-09-30       Impact factor: 5.103

2.  Human Cytomegalovirus Decreases Major Histocompatibility Complex Class II by Regulating Class II Transactivator Transcript Levels in a Myeloid Cell Line.

Authors:  Praneet K Sandhu; Nicholas J Buchkovich
Journal:  J Virol       Date:  2020-03-17       Impact factor: 5.103

3.  Myeloid cell tropism enables MHC-E-restricted CD8+ T cell priming and vaccine efficacy by the RhCMV/SIV vaccine.

Authors:  Scott G Hansen; Meaghan H Hancock; Daniel Malouli; Emily E Marshall; Colette M Hughes; Kurt T Randall; David Morrow; Julia C Ford; Roxanne M Gilbride; Andrea N Selseth; Renee Espinosa Trethewy; Lindsey M Bishop; Kelli Oswald; Rebecca Shoemaker; Brian Berkemeier; William J Bosche; Michael Hull; Lorna Silipino; Michael Nekorchuk; Kathleen Busman-Sahay; Jacob D Estes; Michael K Axthelm; Jeremy Smedley; Danica Shao; Paul T Edlefsen; Jeffrey D Lifson; Klaus Früh; Jay A Nelson; Louis J Picker
Journal:  Sci Immunol       Date:  2022-06-17

Review 4.  Molecular Determinants Regulating the Plasticity of the MHC Class II Immunopeptidome.

Authors:  Laura Santambrogio
Journal:  Front Immunol       Date:  2022-05-16       Impact factor: 8.786

5.  Influenza A Virus Negative Strand RNA Is Translated for CD8+ T Cell Immunosurveillance.

Authors:  Heather D Hickman; Jacqueline W Mays; James Gibbs; Ivan Kosik; Javier G Magadán; Kazuyo Takeda; Suman Das; Glennys V Reynoso; Barbara F Ngudiankama; JiaJie Wei; John P Shannon; Daniel McManus; Jonathan W Yewdell
Journal:  J Immunol       Date:  2018-07-16       Impact factor: 5.422

Review 6.  Lysosomes and lysosome-related organelles in immune responses.

Authors:  Colin Watts
Journal:  FEBS Open Bio       Date:  2022-03-29       Impact factor: 2.792

7.  Vaccinia Virus Vectors Targeting Peptides for MHC Class II Presentation to CD4+ T Cells.

Authors:  Samuel J Hobbs; Jake C Harbour; Phillip A Yates; Diana Ortiz; Scott M Landfear; Jeffrey C Nolz
Journal:  Immunohorizons       Date:  2020-01-02

Review 8.  Moving the Cellular Peptidome by Transporters.

Authors:  Rupert Abele; Robert Tampé
Journal:  Front Cell Dev Biol       Date:  2018-04-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.